Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Gene-Editing Stock to Buy?
We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where ...
Vertex Pharmaceuticals (VRTX) Gets a Hold from Bernstein
In a report released today, William Pickering from Bernstein maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...
Vertex non-opioid painkiller Journavx gets mixed ICER review
ICER's evaluation of Vertex Pharmaceuticals' non-opioid pain drug, Journavx, finds cost-effectiveness related to potential ...
BioSpace1d
Vertex Cuts Diabetes Asset, but Analysts Keen on Phase III Option
Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...
Vertex Pharmaceuticals price target raised to $567 from $555 at BofA
BofA raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $567 from $555 and keeps a Buy rating on the shares. After having ...
Tonix’s Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year
CHATHAM, NJ / ACCESS Newswire / March 31, 2025 /This post was written and published as a collaboration between the in-house ...
Vertex Pharmaceuticals (NasdaqGS:VRTX) Advances Diabetes Portfolio Despite 2% Decline in Share Price
Vertex Pharmaceuticals (NasdaqGS:VRTX) saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The ...
Managed Healthcare Executive4d
Nonopioid Pain Drug Journavx Gaining Traction With High Potential
According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ...
Rattled by the Stock Market Sell-Off? These 3 Stocks Outperformed the S&P 500 During the Great Recession
The economy has been on shaky ground for a while, and President Trump's tariffs and trade wars could finally send it into a ...
Physician's Weekly6d
Addressing Acute Pain & Related Challenges: Will Recent FDA Approval of a Novel Non-Opioid Analgesic Be a Game Changer?
FDA approval of a novel non-opioid analgesic will hopefully address the needs of many patients with acute pain and improve ...